{
    "nct_id": "NCT05846516",
    "official_title": "A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)",
    "inclusion_criteria": "Key inclusion criteria\n\n* Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D or KRAS G12V mutation.\n* ECOG performance status of 0 or 1.\n* Patients with advanced or metastatic disease who completed at least 16 weeks of standard systemic chem-/chemoradiotherapy and achieved a partial response or stable disease.\n* Patients who underwent confirmed R0 or R1 resection and completed at least 3 months of combined peri-adjuvant multiagent chemotherapy.\n* No evidence of disease progression or recurrence.\n* Start of study treatment within 12 weeks from the last curative treatment (resected PDAC).\n* Life expectancy at least 12 months (resected PDAC), or at least 6 months (advanced/metastatic PDAC).\n* Archival tumor tissue availability for central KRAS analysis.\n\nKey exclusion criteria\n\n* Not yet recovered from surgery (resected PDAC).\n* Gastro-intestinal bowel obstruction.\n* Other malignancy within the last 3 years.\n* Prior chemotherapy or targeted small molecule therapy within 14 (locally advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment.\n* Prior radiotherapy within 14 (advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment.\n* Prior use of immunotherapeutic agents, including but not limited to checkpoint inhibitors or VSV-based agents.\n* Diagnosis of immunodeficiency.\n* Chronic systemic treatment with steroids or other immunosuppressive medications.\n* Active autoimmune disease requiring systemic treatment within the last 2 years.\n* Use of Tamoxifen within 1 month prior to start of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}